We investigated the clinical significance of annexin V in the placentae with preeclampsia and found: (1) annexin V was detected on trophoblasts in the placentae and the staining intensity of annexin V in the placentae from such patients was reduced when compared to normal placentae; (2) as expression of annexin V was reduced, the gestosis index from patients with preeclampsia was elevated and the standard deviation value in the infant's standard weight was decreased; plasma level of the fibrin degradation products and thrombin-antithrombin III complex from patients were elevated as the expression of anexin V was reduced. These results suggest that the reduced expression of annexin V in the placentae from patients with preeclampsia may lead to a hypercoagulable state in the intervillous space and may be associated with the development of intrauterine growth restriction.
Introduction
Human placenta is rich in thromboplastin [1] and the plasminogen activator inhibitor [2] that lead to a hypercoagulable state. In contrast, inhibition of platelet aggregation by prostacyclin-like activity [3] , inhibition of blood coagulation by thrombomodulin [4] and fibrinolysis by tissue plasminogen activator [5] play important roles in the regulation of blood coagulation in the placenta. It is known that coagulation abnormalities are present in preeclampsia [6] . Enhanced thrombin formation and endothelial damage are reported in patients with preeclampsia [7] .
Upon the activation of thrombin, phosphatidylserine (PS), which is exclusively located in the cytoplasmic layer of the cell membrane in the resting condition, transferred from the inner to the outer monolayer of the intact membrane [8] . Cell membranes with PS exposed at the outside provide a catalytic surface for coagulation reactions, resulting in a high rate of prothrombinase complex formation and the activation of coagulation [9] . Thrombin and fibrin then activate platelets in the microvillous space, leading to responses such as secretion and aggregation [10] . Recently, as an inhibitor of coagulation through binding with exposed PS, annexin V has been observed. Annexin V was originally purified from human placentae [11] and has potent anticoagulant effects in vitro [12] and in vivo [13] . It inhibits thrombin formation by binding to PS and competing with factor Va and factor Xa in the formation of the prothrombinase complex of factor Vfactor X-phospholipid-Ca 2+ [14, 15] . However, the precise roles of annexin V in intervillous blood fluidity is not completely determined at present. Previous reports demonstrate annexin V localizes to syncytiotrophoblasts and endothelial cells as an intracellular protein and is not present at the cell surface membrane. Therefore, it is suggested that annexin V has no direct antithrombotic factor in the intervillous space but may have an antithrombotic function by inhibiting the tissue factor pathway on damaged trophoblasts in the microvillous space [16] . However, annexin V has recently been immunolocalized to the syncytiotrophoblasts [17] and the microvillar surface of the villous syncytiotrophoblasts [18] . The significant reduction in the expression of annexin V on the placental villi in patients with antiphospholipid syndrome has also been reported [19] . The observations suggest annexin V plays an important role in maintaining the fluidity of intervillous circulation [20, 21] .
In the present study, therefore, we investigated whether annexin V played a role in the pathophysiology of preeclampsia. We examined the immunohistochemical expressions of annexin V in the placentae from patients with preeclampsia and assessed: (1) the correlation between the expression of annexin V and the gestosis index (GI) of patients with preeclampsia; (2) the correlation between the expression of annexin V and the standard deviation (SD) values of the infants' standard weight at gestational weeks; (3) the correlation between the expression of annexin V and valuables in the coagulation/fibrinolysis system.
Materials and Methods

Placental Tissues
Placentae from 17 preeclamptic patients and 7 healthy pregnant women were obtained after delivery at the Department of Obstetrics and Gynecology, Hamamatsu University Hospital, from 1993 to 1997. The healthy pregnant women had appropriately-grown fetuses and full-term deliveries. Preeclampsia was diagnosed according to the criteria for evaluation of the severity of preeclampsia by the Committee of Preeclampsia (1985) of the Japanese Society of Obstetrics and Gynecology. The severity of toxemia was classified using the GI, which is the scoring system of the Organization Gestosis (table 1) . Each 10-mm fragment was immediately fixed in 3.5% paraformaldehyde, and then embedded in paraffin wax. Pathological changes were studied after staining of the sections with hematoxylin and eosin (HE).
Primary Antibodies
Two monoclonal antibodies were employed. Specificities, references, sources and dilution are detailed as follows: monoclonal antibody against human annexin V (Kowa, Nagoya, Japan; 1:25 dilution) and monoclonal antibody against human fibrin (American Diagnostica, Inc., Conn., USA; 1:25 dilution).
Immunohistochemistry
The intensity and distribution of annexin V in the placentae were examined using an immunohistochemical method. Sections were labeled using the following indirect immunoperoxidase: Paraffinembedded tissues were cut into a thickness of 3 Ìm and placed on glass slides coated wtih 1% poly-c-lysine. After deparaffinization in xylene and graded ethanol, the specimens were soaked in methanol containing 1% hydrogen peroxide for 20 min in order to remove intrinsic peroxidase. The sections were then washed with 0.01 M sodium phosphate-buffered saline (PBS), pH 7.4, and then incubated with 20% rabbit serum for 20 min. Primary monoclonal antibodies diluted with PBS were incubated for 16 h at 4°C, then washed with PBS 3 times. A streptavidin-peroxidase kit (Dako, Glostrup, Denmark) was then used. The sections were sequentially incubated with biotinylated goat IgG fraction anti-mouse IgG for 30 min, and incubated with streptavidin-peroxidase for 30 min. Finally, slides were reacted with a 3% 3-amino-9-ethylcarbazole substrate for 5 min at 23°C. Sections were lightly counterstained with Mayer's hematoxylin, dehydrated, cleared and mounted in synthetic resin. Controls were performed by replacing the first antibody with mouse IgG. 
Statistical Analysis
The SD value of the infants' standard weight at gestational weeks was determined based on the NISHIDA fetal growth curve [22] . Plasma fibrin degradation product (FDP) and thrombin-antithrombin III complex (TAT) levels were also measured. The correlations between the immunohistochemical expression of annexin V and GI, SD, FDP and TAT were statistically analyzed using Spearman's rank correlation methods.
Results
A description of the subjects' personal characteristics is given in table 2. Patients 1-17 had preeclampsia, 2 of them with GI 3, 6 with GI 4-5, 5 with GI 6-9 and 4 with GI 10. The mean GI was 6.76 B 2.66. Patients 18-24 were normal pregnant women.
Immunohistochemistry
The staining intensities of annexin V were graded by two pathologists uninformed of the background of the patients (table 2) . Weak, moderate and strong stainings were graded (1+), (2+) or (3+), respectively. Normal placentae without reduction of the annexin V expression were strongly stained and graded as (3+). The negative controls were graded (-). There was no significant difference in the immunohistochemical staining intensity in the same microscopic field. Results of the immunohistochemical study in preeclamptic patients (GI 7) and a normal pregnant woman are shown in figures 1 and 2, respectively. HE stainings are shown as (a), annexin V stainings as (b), controls as (c) and the stainings of fibrin as (d). The HE stainig of the placenta from the preeclamptic patients showed trophoblasts with diffuse fibrin depositions and syncytial knots formation ( fig. 1a, d ). Annexin V was distributed in cytosol and on the surface of the placental villi Shu/Sugimura/Kanayama/Kobayashi/ Kobayashi/Terao syncytiotrophoblasts. The staining intensity of annexin V ( fig. 1b ) in the placenta with preeclampsia (grade 1+) was more reduced than in normal placenta ( fig. 2b ) with 3+ on a graded scale. There was also a significant inverse correlation between the TAT and the expression of annexin V (r = -0.482, p ! 0.05).
Statistical Analysis
Discussion
In the present study, we have demonstrated that the expression of annexin V is reduced in the placenta with preeclampsia and the graded immunohistochemical expression of annexin V is correlated with the severity of preeclampsia.
The microscopic and immunohistochemical studies showed trophoblasts in the placental intervillous space in patients with preeclampsia and revealed the diffuse fibrin depositions compared with the placenta of a normal pregnancy. As trophoblasts are damaged in preeclampsia, the fibroblasts in mesenchyme [23] or the decidual cells with the tissue factor beneath the trophoblast cell layer are directly exposed to the maternal circulation followed by the activation of the extrinsic pathway of blood coagulation and then following thrombin formation. Our results indicate that thrombin formation in the intervillous space is enhanced in preeclamptic patients.
The immunohistochemical study of annexin V showed that the staining intensities of annexin V in placentae from preeclamptic patients were reduced when compared to normal placentae. There are two possibilities that explain this observation. First, the reduced intensity of annexin V may be a result of trophoblast dysfunction in preeclampsia. When trophoblasts are damaged, annexin V productions in the intervillous space are reduced. Second, the reduced expression of annexin V due to an unknown reason may decrease the binding of annexin V to the exposed PS. As a result, it leads to the hypercoagulation in preeclampsia. Though it is still unclear whether the reduction in the annexin V expression is the result or the cause of hypercoagulation in the intervillous space, we hypothesize that the reduced level of annexin V in syncytiotrophoblast cells may increase thrombin formation in preeclampsia.
In addition, the results showing significant inverse correlations between the coagulation/fibrinolysis system markers and the expression of annexin V suggest that the reduced expression of annexin V in the placentae is closely associated with the increased thrombin formation. An analysis of the correlations between the expression of annexin V and clinical data show that the reduced expression of annexin V is correlated with the severity of the preeclampsia. Furthermore, the analysis of the correlations between the expression of annexin V and the SD values of the infants' standard weights show that the development of IUGR may partly be due to the reduced expression of annexin V in the preeclampsia patients. IUGR is considered to be associated with the reduction in uteroplacental circulation induced by vasoconstriction and hypercoagulation caused by increased thrombin formation [24] . We, therefore, suggest that the reduced expression of annexin V in patients with preeclampsia might enhance fibrin formation in the placenta and lead to placental dysfunction with the development of IUGR.
In summary, our study suggests that the reduction of annexin V in the placentae from preeclamptic patients is closely associated with the hypercoagulability state in the intervillous space and possibly associated with the pathogenesis of IUGR.
